Rivaroxaban Tablet, Film Coated
Product Images NDC 72603-890

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 72603-890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

556 (Rivaroxaban Fig 02)

A forest plot showing fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of rivaroxaban in various populations including end-stage renal disease, renal impairment (severe, moderate, mild), different age groups, body weight categories, and hepatic impairment levels. The x-axis represents fold change relative to normal reference values.*

FDA Label Image

565 (Rivaroxaban Fig 03)

A horizontal bar chart depicting fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of rivaroxaban when coadministered with various interacting drugs. The drugs are grouped into Combined P-gp and Strong CYP3A Inhibitors (Ketoconazole, Ritanovir, Clarithromycin), Combined P-gp and Moderate CYP3A Inhibitors (Erythromycin), Moderate CYP3A Inhibitor (Fluconazole), Combined P-gp and Strong CYP3A Inducer (Rifampicin), and Other Drugs including aspirin, atorvastatin, clopidogrel, digoxin, enoxaparin, mafenide, midazolam, naproxen, omeprazole, ranitidine, and warfarin. The x-axis shows fold change relative to rivaroxaban alone on a logarithmic scale from 0.25 to 4.*

FDA Label Image

505 (Rivaroxaban Fig 09)

A forest plot comparing the primary efficacy outcome (composite of stroke, myocardial infarction, or cardiovascular death) between Rivaroxaban and Placebo across various subgroups. Subgroups include age, sex, region, weight, estimated glomerular filtration rate (eGFR), myocardial infarction history, stroke history, prior heart failure, baseline diabetes, and peripheral artery disease (PAD). The plot shows hazard ratios with 95% confidence intervals, indicating relative treatment effects.*

FDA Label Image

458 (Rivaroxaban Figure 10)

A cumulative incidence rate chart comparing Rivaroxaban and Placebo over time in days from randomization up to 1095 days. The chart includes a survival analysis curve with Rivaroxaban showing lower cumulative incidence rates than Placebo. It also presents the number of subjects at risk for each treatment group at multiple time points and the hazard ratio of 0.74 (95% CI 0.65-0.86) comparing Rivaroxaban to Placebo.*

FDA Label Image

569 (Rivaroxaban Figure 11)

A line chart depicting the cumulative incidence rate (%) over days from randomization for two treatment groups: Rivaroxaban and placebo. The chart includes a legend identifying solid line for Rivaroxaban and dashed line for placebo. A table below the x-axis shows the number of subjects at risk over time intervals for both groups. The chart also includes a hazard ratio comparison between Rivaroxaban and placebo with a value of 0.85 (95% CI: 0.76, 0.96).*

FDA Label Image

505 (Rivaroxaban Figure 12)

A forest plot chart comparing the primary efficacy outcomes of Rivaroxaban versus placebo across various patient subgroups including age, sex, weight, kidney function (eGFR), diabetes status, coronary artery disease (CAD), randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The chart shows hazard ratios (HR) with 95% confidence intervals indicating the effectiveness of Rivaroxaban relative to placebo.*

FDA Label Image

Str (Rivaroxaban Str)

Chemical structure of rivaroxaban, a pharmaceutical active ingredient, showing its molecular connectivity and arrangement of atoms.*

FDA Label Image

878 (Rivaroxaban Tablets 2 5mg 60s)

Label for Rivaroxaban Tablets, USP 2.5 mg oral film-coated tablets by NorthStar Rx LLC. The label indicates a package containing 60 tablets, with storage instructions and manufacturer information, including Macleods Pharmaceuticals Ltd. It includes barcodes and a note to dispense the Medication Guide separately.*

FDA Label Image

787 (Rivaroxaban Tablets 25 mg 180s)

Label for Rivaroxaban Tablets, USP 2.5 mg oral film-coated tablets. The label indicates a package contains 180 tablets. It is manufactured by Macleods Pharmaceuticals Ltd. and labeled by NorthStar Rx LLC. Storage instructions and a pharmacist dispensing note are included, along with barcodes and contact information for the Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.